Matthew Abernethy compensation by year
NEUROCRINE BIOSCIENCES Summary Compensation Table · all 6 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $38,231 | $420,000 | $495,600 | $545,200 | $588,800 | $725,913 |
| Bonus | $20,071 | $199,500 | $284,970 | $190,820 | $264,960 | $526,000 |
| Stock awards | $920,000 | $1,996,506 | $1,250,035 | $2,500,266 | $2,375,068 | $2,499,918 |
| Option awards | $2,416,800 | $0 | $3,750,345 | $2,999,869 | $2,625,019 | $2,500,036 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $394,190 | $69,741 | $42,170 | $45,021 | $53,003 | $60,045 |
| Total | $3,789,292 | $2,685,747 | $5,823,120 | $6,281,176 | $5,906,850 | $6,311,912 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEUROCRINE BIOSCIENCES INC DEF 14A filed April 15, 2026, accession 0000914475-26-000015, and prior-year filings. Open the filing on EDGAR.
How this page was built: the NEUROCRINE BIOSCIENCES INC filed document, accession 0000914475-26-000015. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 12,801 | $1,815,566 | — |
| RSU | 10,040 | $1,423,973 | — |
| RSU | 9,968 | $1,413,761 | — |
| RSU | 8,534 | $1,210,377 | — |
| RSU | 6,725 | $953,807 | — |
| RSU | 5,132 | $727,872 | — |
| RSU | 2,437 | $345,640 | — |
| Option | 36,051 | — | $117.18 |
| Option | 1,383 | — | $79.02 |
| Option | 24,406 | — | $133.84 |
| Option | 18,605 | — | $103.52 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NEUROCRINE BIOSCIENCES INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
NEUROCRINE BIOSCIENCES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kyle Gano | Chief Executive Officer and Director | $13,448,935 |
| Sanjay Keswani | Chief Medical Officer | $9,007,803 |
| Jude Onyia | Chief Scientific Officer | $7,410,769 |
| Matthew Abernethy · this page | Chief Financial Officer | $6,311,912 |
| Eiry Roberts | Strategic Advisor | $6,073,032 |
| Eric Benevich | Chief Commercial Officer | $5,888,947 |
Matthew Abernethy's compensation dossier, NEUROCRINE BIOSCIENCES
You have read Matthew Abernethy's totals and holdings. The dossier adds each equity grant NEUROCRINE BIOSCIENCES disclosed for Matthew Abernethy and NEUROCRINE BIOSCIENCES's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full NEUROCRINE BIOSCIENCES compensation record
free company briefThis page is one person within NEUROCRINE BIOSCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NEUROCRINE BIOSCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NEUROCRINE BIOSCIENCES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEUROCRINE BIOSCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order NBIX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.